SEARCH

SEARCH BY CITATION

References

  • 1
    Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008; 23(8):115567.
  • 2
    Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tankó LB. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol. 2006; 62:78192.
  • 3
    Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001; 12:98995.
  • 4
    Burr DB. Cortical bone: a target for fracture prevention?. Lancet. 2010; 375:16723.
  • 5
    Holzer G, von Skrbensky G, Holzer LA, Pichl W. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res. 2009; 24:46874.
  • 6
    Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375:172936.
  • 7
    Hartholt KA, Oudshoorn C, Zielinski SM, Burgers PT, Panneman MJ, van Beeck EF, Patka P, van der Cammen TJ. The epidemic of hip fractures: are we on the right track?. PLoS One. 2011; 6:e22227.
  • 8
    Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, Phelps ME, Hawkins RA. Bone metabolic activity measured with positron emission tomography and 18F-fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endo Metab. 1993; 77:94955.
  • 9
    Piert M, Zittel TT, Becker GA, Jahn M, Stahlschmidt A, Maier G, Machulla HJ, Bares R. Assessment of porcine bone metabolism by dynamic 18F-fluoride PET: correlation with bone histomorphometry. J Nucl Med. 2001; 42:1091100.
  • 10
    Hawkins RA, Choi Y, Huang S-C, Hoh CK, Dahlbom M, Schiepers C, Satyamurthy N, Barrio JR, Phelps ME. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992; 33:63342.
  • 11
    Siddique M, Frost ML, Blake GM, Moore AE, Al-Beyatti Y, Marsden PK, Schleyer PJ, Fogelman I. The precision and sensitivity of 18F-fluoride PET for measuring regional bone metabolism: a comparison of quantification methods. J Nucl Med. 2011; 52:174855.
  • 12
    Cook GJR, Blake GM, Marsden PK, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res. 2002; 17:8549.
  • 13
    Frost ML, Fogelman I, Blake GM, Marsden PK, Fogelman I. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res. 2004; 19:1797804.
  • 14
    Frost ML, Blake GM, Cook GJ, Marsden PK, Fogelman I. Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: 18F-fluoride PET study of treatment-naïve and treated postmenopausal women. Bone. 2009; 45:9428.
  • 15
    Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M. 18F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med. 2005; 46:16508.
  • 16
    Piert M, Zittel TT, Jahn M, Stahlschmidt A, Becker GA, Machulla H-J. Increased sensitivity in detection of a porcine high-turnover osteopenia after total gastrectomy by dynamic 18F-fluoride ion PET and quantitative CT. J Nucl Med. 2003; 44:11724.
  • 17
    Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997; 38:19706.
  • 18
    Berding G, Burchert W, van den Hoff J, Pytlik C, Neukam FW, Meyer GJ, Gratz KF, Hundeshagen H. Evaluation of the incorporation of bone grafts used in maxillofacial surgery with 18F-fluoride ion and dynamic positron emission tomography. Eur J Nucl Med. 1995; 22:113340.
  • 19
    Brenner W, Vernon C, Muzi M, Mankoff DA, Link JM, Conrad EU, Eary JF. Comparison of different quantitative approaches to 18F-fluoride PET scans. J Nucl Med. 2004; 45:1493500.
  • 20
    Hsu WK, Feeley BT, Krenek L, Stout DB, Chatziioannou AF, Lieberman JR. The use of 18F-fluoride and 18F-FDG PET scans to assess fracture healing in a rat femur model. Eur J Nucl Med Mol Imaging. 2007; 34:1291301.
  • 21
    Piert M, Winter E, Becker GA, Bilger K, Machulla H, Müller-Schauenburg W, Bares R, Becker HD. Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic 18F-fluoride ion positron emission tomography. Eur J Nucl Med. 1999; 26:61524.
  • 22
    Frost ML, Cook GJ, Blake GM, Marsden PK, Benatar NA, Fogelman I. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res. 2003; 18:221522.
  • 23
    Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT, Somer EJ, Marsden PK, Eastell R, Fogelman I. Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography. J Bone Miner Res. 2011; 26:100211.
  • 24
    Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, Tsuchida T, Okazawa H, Fujibayashi Y, Baba H. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med. 2009; 50:180814.
  • 25
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Support Series, No 843 Geneva, Switzerland: WHO, 1994.
  • 26
    Cook GJR, Lodge MA, Marsden PK, Dynes A, Fogelman I. Non-invasive assessment of skeletal kinetics using fluorine-18-fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. Eur J Nuc Med. 1999; 26:14249.
  • 27
    Blake GM, Siddique M, Puri T, Frost ML, Moore AE, Cook GJ, Fogelman I. A semipopulation input function for quantifying static and dynamic 18F-fluoride PET scans. Nucl Med Commun. 2012; 33:8818.
  • 28
    Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3:17.
  • 29
    Siddique M, Blake GM, Frost ML, Moore AE, Puri T, Marsden PK, Fogelman I. Estimation of regional bone metabolism from whole-body 18F-Fluoride PET Static Images. Eur J Nuc Med Mol Imaging. 2012; 39:33743.
  • 30
    Moore AE, Blake GM, Taylor KA, Rana AE, Wong M, Chen P, Fogelman I. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res. 2010; 25:9607.
  • 31
    Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH. Teriparatide [PTH(1–34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004; 19:6239.
  • 32
    Bjørnerem Å, Ghasem-Zadeh A, Bui M, Wang X, Rantzau C, Nguyen TV, Hopper JL, Zebaze R, Seeman E. Remodeling markers are associated with larger intracortical surface area but smaller trabecular surface area: a twin study. Bone. 2011; 49:112530.
  • 33
    Dalstra M, Huiskes R. Load transfer across the pelvic bone. J Biomechanics. 1995; 28:71524.
  • 34
    Hagino H, Okano T, Akhter MP, Enokida M, Teshima R. Effect of parathyroid hormone on cortical bone response to in vivo external loading of the rat tibia. J Bone Miner Metab. 2001; 19:24450.
  • 35
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349:120715.
  • 36
    Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res. 2010; 25:47281.
  • 37
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350:5505.
  • 38
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of recombinant human parathyroid hormone (1–34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med. 2001; 344:143441.
  • 39
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006; 91:13705.
  • 40
    Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003; 88:521220.
  • 41
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85:306976.
  • 42
    Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL. Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18:53943.
  • 43
    Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16:15765.
  • 44
    Burr DB. Does early PTH treatment compromise bone strength? The balance between remodelling, porosity, bone mineral, and bone size. Curr Osteoporos Rep. 2005; 3:1924.
  • 45
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18:193241.
  • 46
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005; 353:55565.
  • 47
    Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31:2849.